Akeso, Inc. Overview
Pro stress-test →Akeso is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of antibody drugs covering therapeutic areas of oncology, autoimmune and metabolic diseases. The company has a pipeline of over 30 drugs, with 17 having entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF).
Strategic Profile
Pro stress-test →Headquartered in Zhongshan, China, with a goal of becoming a global leader in innovative therapeutic antibodies, the company operates a diversified antibody drug pipeline covering over 20 drug development programs. Recent clinical data shows Akeso's immunotherapy drug has outperformed leading Western peers in studies, earning recognition as the 'DeepSeek moment' for China's drug industry.
Competitive Landscape
Pro stress-test →Direct competitors in Chinese biotech include Innovent Biologics, RemeGen, Shanghai Junshi Biosciences, Shanghai Henlius Biotech, and others. Akeso differentiates through first-in-class bi-specific antibodies (PD-1/CTLA-4, PD-1/VEGF) with superior clinical efficacy compared to established Western competitors like Merck and BioNTech in oncology immunotherapy.
Industry Context
Akeso, Inc. operates in Biopharmaceutical/Oncology Immunotherapy.
Key facts
Founded: 2012 · Headquarters: Zhongshan, China · Employees: 3,529 · Market cap: $93.68B HKD